Initial Statement of Beneficial Ownership (3)
October 08 2021 - 6:00PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
GRAINGER DAVID J |
2. Date of Event Requiring Statement (MM/DD/YYYY)
10/1/2021
|
3. Issuer Name and Ticker or Trading Symbol
Centessa Pharmaceuticals plc [CNTA]
|
|
(Last)
(First)
(Middle)
C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Innovation Officer / |
|
(Street)
CHESHIRE, X0 WA14 2DT
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Ordinary Shares (1) | 813756 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Share Option (right to buy) | (2) | 5/7/2031 | Ordinary Shares (1) | 150000 | $9.42 | D | |
| Explanation of Responses: |
| (1) | The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| (2) | 25% of the shares subject to such option shall vest and become exercisable on May 7, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. |
Remarks:
Exhibit 24 - Power of Attorney |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
GRAINGER DAVID J
C/O CENTESSA PHARMACEUTICALS PLC
3RD FL., 1 ASHLEY RD, ALTRINCHAM
CHESHIRE, X0 WA14 2DT |
|
| Chief Innovation Officer |
|
Signatures
|
| /s/ Marella Thorell, attorney-in-fact | | 10/8/2021 |
| **Signature of Reporting Person | Date |
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Jul 2023 to Jul 2024
